AR008198A1 - PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION OF 5- [4- [2- (N- METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIN-2,4-DIONA - Google Patents
PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION OF 5- [4- [2- (N- METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIN-2,4-DIONAInfo
- Publication number
- AR008198A1 AR008198A1 ARP980102649A ARP980102649A AR008198A1 AR 008198 A1 AR008198 A1 AR 008198A1 AR P980102649 A ARP980102649 A AR P980102649A AR P980102649 A ARP980102649 A AR P980102649A AR 008198 A1 AR008198 A1 AR 008198A1
- Authority
- AR
- Argentina
- Prior art keywords
- thiazolin
- amino
- methyl
- preparing
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Un procedimiento para preparar una composición farmacéutica que comprende de 2 a 12 mg de 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona [Compuesto (I)] en una forma farmacéuticamente aceptable y un vehículo para elmismo farmacéuticamente aceptable, que comprende mezclar2 a 12 mg de Compuesto (I) en una forma farmacéuticamente aceptable y opcionalmente, después de ello, formular la composición producida en una formaadministrable. El compuesto (I) proporciona un efecto especialmente beneficioso sobre el control glicémico y, por lo tanto, es particularmente útil para eltratamiento de la diabetes mellitus, especialmente la diabetes de tipo II, y los trastornos asociados con la diabetes mellitus.A method of preparing a pharmaceutical composition comprising 2 to 12 mg of 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolin-2,4-dione [Compound (I)] in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier therefor, comprising mixing 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally thereafter formulating the produced composition in an administrable form. Compound (I) provides an especially beneficial effect on glycemic control and is therefore particularly useful for the treatment of diabetes mellitus, especially type II diabetes, and disorders associated with diabetes mellitus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9711683.4A GB9711683D0 (en) | 1997-06-05 | 1997-06-05 | Composition |
| GBGB9712851.6A GB9712851D0 (en) | 1997-06-18 | 1997-06-18 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008198A1 true AR008198A1 (en) | 1999-12-29 |
Family
ID=26311662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102649A AR008198A1 (en) | 1997-06-05 | 1998-06-04 | PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION OF 5- [4- [2- (N- METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIN-2,4-DIONA |
| ARP980102650A AR015120A1 (en) | 1997-06-05 | 1998-06-04 | PHARMACEUTICAL COMPOSITION THAT INCLUDES 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] -TIAZOLIDIN-2,4-DIONA, A PROCEDURE FOR PREPARATION, AND A PREPARATION FOR PRE -PHARMACEUTICAL ADMINISTRATION |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102650A AR015120A1 (en) | 1997-06-05 | 1998-06-04 | PHARMACEUTICAL COMPOSITION THAT INCLUDES 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] -TIAZOLIDIN-2,4-DIONA, A PROCEDURE FOR PREPARATION, AND A PREPARATION FOR PRE -PHARMACEUTICAL ADMINISTRATION |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0998284A1 (en) |
| JP (1) | JP2001521553A (en) |
| KR (1) | KR20010013410A (en) |
| CN (3) | CN1526391A (en) |
| AP (1) | AP1214A (en) |
| AR (2) | AR008198A1 (en) |
| AU (1) | AU8215098A (en) |
| BG (1) | BG104048A (en) |
| BR (1) | BR9810405A (en) |
| CA (2) | CA2333352A1 (en) |
| CO (1) | CO4940400A1 (en) |
| DZ (1) | DZ2510A1 (en) |
| EA (1) | EA002384B1 (en) |
| GB (1) | GB9711683D0 (en) |
| HU (1) | HUP0004070A3 (en) |
| ID (1) | ID24264A (en) |
| IL (1) | IL133074A0 (en) |
| MX (1) | MXPA99011322A (en) |
| NO (2) | NO995938L (en) |
| NZ (2) | NZ523725A (en) |
| OA (1) | OA11306A (en) |
| PE (1) | PE78899A1 (en) |
| PL (1) | PL337201A1 (en) |
| SK (1) | SK164899A3 (en) |
| TR (2) | TR199902963T2 (en) |
| TW (1) | TW570797B (en) |
| UY (1) | UY25032A1 (en) |
| WO (1) | WO1998055122A1 (en) |
| ZA (2) | ZA984826B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE246191T1 (en) | 1999-04-23 | 2003-08-15 | Smithkline Beecham Plc | POLYMORPHOUS OF 5-(4-(2-(N-METHYL-N-(2-PYRDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MALEIC ACID SALT |
| US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| KR100744359B1 (en) | 1999-04-23 | 2007-07-30 | 스미스클라인비이참피이엘시이 | Thiazolidinedione Derivative and its Use as Antidiabetic |
| GB0021978D0 (en) | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
| WO2003050112A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Toluenesulfonate hydrates of a thiazolidinedione derivative |
| GB0129876D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0129871D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0130509D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| EP1854794A1 (en) * | 2006-05-09 | 2007-11-14 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3856378T2 (en) * | 1987-09-04 | 2000-05-11 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| SG47100A1 (en) * | 1994-02-10 | 1998-03-20 | Smithkline Beecham Plc | Use of insulin sensitisers for treating renal diseases |
| KR19990036290A (en) * | 1995-08-10 | 1999-05-25 | 로즈 암스트롱 | Reduction of Exogenous Insulin Dosage in Non-insulin-Dependent Diabetic Patients |
| AU7604596A (en) * | 1995-11-17 | 1997-06-11 | Warner-Lambert Company | A method of treating myotonic dystrophy |
| IL120443A (en) * | 1996-03-18 | 2000-07-16 | Sankyo Co | Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis |
| AU3552697A (en) * | 1996-07-12 | 1998-02-09 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
-
1997
- 1997-06-05 GB GBGB9711683.4A patent/GB9711683D0/en active Pending
-
1998
- 1998-06-02 EA EA199901116A patent/EA002384B1/en not_active IP Right Cessation
- 1998-06-02 CA CA002333352A patent/CA2333352A1/en not_active Abandoned
- 1998-06-02 MX MXPA99011322A patent/MXPA99011322A/en unknown
- 1998-06-02 KR KR19997011411A patent/KR20010013410A/en not_active Application Discontinuation
- 1998-06-02 JP JP50158799A patent/JP2001521553A/en not_active Ceased
- 1998-06-02 TR TR1999/02963T patent/TR199902963T2/en unknown
- 1998-06-02 AP APAP/P/1999/001696A patent/AP1214A/en active
- 1998-06-02 WO PCT/EP1998/003478 patent/WO1998055122A1/en not_active Application Discontinuation
- 1998-06-02 CN CNA2003101199090A patent/CN1526391A/en active Pending
- 1998-06-02 BR BR9810405-5A patent/BR9810405A/en not_active IP Right Cessation
- 1998-06-02 NZ NZ523725A patent/NZ523725A/en unknown
- 1998-06-02 IL IL13307498A patent/IL133074A0/en unknown
- 1998-06-02 PL PL98337201A patent/PL337201A1/en unknown
- 1998-06-02 TR TR2000/02790T patent/TR200002790T2/en unknown
- 1998-06-02 ID IDW991520A patent/ID24264A/en unknown
- 1998-06-02 HU HU0004070A patent/HUP0004070A3/en unknown
- 1998-06-02 EP EP98932144A patent/EP0998284A1/en not_active Withdrawn
- 1998-06-02 CN CN98805686A patent/CN1112926C/en not_active Expired - Lifetime
- 1998-06-02 AU AU82150/98A patent/AU8215098A/en not_active Abandoned
- 1998-06-02 SK SK1648-99A patent/SK164899A3/en unknown
- 1998-06-02 CA CA002292629A patent/CA2292629C/en not_active Expired - Fee Related
- 1998-06-03 DZ DZ980120A patent/DZ2510A1/en active
- 1998-06-04 AR ARP980102649A patent/AR008198A1/en not_active Application Discontinuation
- 1998-06-04 ZA ZA9804826A patent/ZA984826B/en unknown
- 1998-06-04 UY UY25032A patent/UY25032A1/en not_active IP Right Cessation
- 1998-06-04 AR ARP980102650A patent/AR015120A1/en not_active Application Discontinuation
- 1998-06-04 CO CO98031614A patent/CO4940400A1/en unknown
- 1998-06-04 ZA ZA9811572A patent/ZA9811572B/en unknown
- 1998-06-05 PE PE1998000466A patent/PE78899A1/en not_active Application Discontinuation
- 1998-10-23 TW TW087117536A patent/TW570797B/en not_active IP Right Cessation
-
1999
- 1999-12-02 OA OA9900267A patent/OA11306A/en unknown
- 1999-12-03 NO NO995938A patent/NO995938L/en not_active Application Discontinuation
- 1999-12-27 BG BG104048A patent/BG104048A/en unknown
-
2001
- 2001-09-03 NZ NZ513922A patent/NZ513922A/en unknown
-
2002
- 2002-11-05 CN CN02149972A patent/CN1430959A/en active Pending
-
2004
- 2004-02-20 NO NO20040738A patent/NO20040738L/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057970A2 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS DIABETES AND CONDITIONS ASSOCIATED WITH MELLITUS DIABETES AND PROCEDURES TO PREPARE SUCH COMPOSITIONS | |
| UY25049A1 (en) | TREATMENT COMPOSITIONS FOR DIABETES MELLITUS | |
| EA200601145A1 (en) | TABLET OF SLOW-DIVISION OF INSULIN SENSITIZER AND OTHER ANTI-DIABETIC AGENTS | |
| AR008198A1 (en) | PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION OF 5- [4- [2- (N- METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIN-2,4-DIONA | |
| CO4940454A1 (en) | NEW METHOD OF TREATMENT | |
| BR0114196A (en) | Polymorphic forms of 5- [4- [2- [n-methyl-n- (2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and process for the preparation thereof. | |
| UY25102A1 (en) | NEW COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS | |
| EA200601144A1 (en) | TABLET OF SLOW-DOWN PREVENTION OF INSULIN SENSITIZER TO INSULIN | |
| NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| PE108199A1 (en) | PHARMACEUTICAL COMPOSITION OF TIAZOLIDINDIONA AND SULFONILUREA | |
| UY26112A1 (en) | 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIDINE-2,4-DIONA HYDROCHLORIDE | |
| UY25051A1 (en) | COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS | |
| AP1715A (en) | The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione | |
| AU2002343052A1 (en) | Rosiglitazone edisylates and their use as antidiabetics | |
| AU2001284285A1 (en) | A thiazolidinedione derivative and its use as antidiabetic | |
| BR0111536A (en) | Thiazolidinedione salt for diabetes mellitus treatment | |
| AP1841A (en) | A thiazolidinedione derivative and its use as antidiabetic. | |
| UY25801A1 (en) | PROCEDURE FOR PREPARING COMPOSITIONS FOR THE TREATMENT OF DIABETES. | |
| NZ510672A (en) | Composition comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)-Ethoxy]Benzyl]Thiazolidine-2,4-Dione | |
| EA200300004A1 (en) | HYDROIODID 5- [4- [2- (N-METHYL-N- (2-Pyridyl) AMINO) ETOXY] BENZYL] THIAZOLIDIN-2,4-DIONA AS PHARMACEUTICAL PREPARATION | |
| CO5150180A1 (en) | NEW COMPOSITION AND USE MODIFIED RELEASE | |
| ECSP003434A (en) | NEW COMPOUNDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |